HOME › DRUGS › CARMUSTINE
ACTIVE SUBSTANCE / INN

CARMUSTINE

Brand name(s): GLIADEL, BICNU, Carmustine medac (previously Carmustine Obvius), CARMUSTINE
FDA LISTED
EMA LISTED
PRESCRIPTION
DISCONTINUED
AUTHORISED
Hodgkin Disease;Lymphoma, Non-Hodgkin
NDA017422
ACTIVE SUBSTANCE
Carmustine
REGULATORS
FDA · EMA
SPONSORS / MAH
AZURITY, AVET LIFESCIENCES, PHARMOBEDIENT
TOTAL APPLICATIONS
5
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
CARMUSTINEANDA209278PENN LIFEPrescription
CARMUSTINEANDA215368PHARMOBEDIENTDiscontinued
GLIADELNDA020637AZURITYPrescription
BICNUNDA017422AVET LIFESCIENCESPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Carmustine medac (previously Carmustine Obvius)medac Gesellschaft für klinische Spezialpräparate mbHAuthorised18/07/2018Hodgkin Disease;Lymphoma, Non-Hodgkin

FULL INTELLIGENCE ON CARMUSTINE

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →